Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.9%

7 terminated/withdrawn out of 370 trials

Success Rate

89.9%

+3.3% vs industry average

Late-Stage Pipeline

9%

32 trials in Phase 3/4

Results Transparency

0%

0 of 62 completed trials have results

Key Signals

111 recruiting

Enrollment Performance

Analytics

N/A
101(40.6%)
Phase 2
74(29.7%)
Phase 1
39(15.7%)
Phase 3
22(8.8%)
Phase 4
10(4.0%)
Early Phase 1
3(1.2%)
249Total
N/A(101)
Phase 2(74)
Phase 1(39)
Phase 3(22)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (370)

Showing 20 of 370 trials
NCT07153848Recruiting

An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease

Role: lead

NCT06211439Not ApplicableCompleted

Transcranial Alternating Current Stimulation in Patients With Disorders of Consciousness

Role: lead

NCT07735182Recruiting

Microbiome and Enteric Signatures in Sepsis-associated Hepatorenal Injury

Role: lead

NCT07694921Not ApplicableEnrolling By Invitation

Effect and Safety of Non-invasive Electrical Stimulation in Alzheimer's Disease

Role: lead

NCT05413343Active Not Recruiting

Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients

Role: lead

NCT07362797Not ApplicableNot Yet Recruiting

Video-guided Versus Conventional Right-sided Double-Lumen Tubes for One-Lung Ventilation in Thoracoscopic Surgery

Role: collaborator

NCT07718503Not ApplicableNot Yet Recruiting

A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut Microbiota

Role: lead

NCT07707687Phase 2Recruiting

Safety and Efficacy of Eculizumab in High-risk TA-TMA

Role: lead

NCT07692841Phase 3Recruiting

Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors

Role: lead

NCT07184853Not ApplicableRecruiting

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

Role: lead

NCT07423728Not ApplicableRecruiting

CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors

Role: lead

NCT07667517Phase 4Not Yet Recruiting

Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease

Role: lead

NCT07665359Not ApplicableNot Yet Recruiting

Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD

Role: collaborator

NCT07654348Phase 2Not Yet Recruiting

Efficacy and Mechanism of IPSRT for Bipolar II Disorder

Role: lead

NCT07209787Phase 4Recruiting

SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak

Role: collaborator

NCT07651163Phase 2Enrolling By Invitation

Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy

Role: lead

NCT07651176Phase 2Enrolling By Invitation

Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy

Role: lead

NCT07640438Phase 1Recruiting

Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ

Role: lead

NCT07635992Phase 1Not Yet Recruiting

A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV

Role: lead

NCT07621562Phase 2Not Yet Recruiting

Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer

Role: lead